Skip to main navigation

Skip to content

Customer Service: 866-788-9007

PHYSICIAN LOGIN | CRF LOGIN

ORDER TEST

Company
Products
Research & Development
Investors
Scientific Publications
Resources

March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic

Email Alerts

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
End of the Day SEC Filing
Event
News

Email

Latest News

Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic March 27, 2020
Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma March 26, 2020
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results March 10, 2020
Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma March 5, 2020
Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 February 25, 2020

Site - Investor Tools

Print Page

RSS Feeds

Email Alerts

Investor Contact

Investor Contact

Search

Connect with Us

Company

About Us
History
Leadership
- Executive Management
- Board of Directors
Licenses
Careers
Contact Us

Products

Cutaneous Melanoma
- DecisionDx-Melanoma
- DecisionDx-CMSeq
Uveal Melanoma

Research & Development

Our Approach
Tests in Development
Cutaneous Squamous Cell Carcinoma
Suspicious Pigmented Lesions

Latest News & Publications

Press Releases
Scientific Publications
Email Alerts

Resources

Healthcare Professionals
Patients

Copyright © 2020 Castle Biosciences, Inc. | All Rights Reserved

Privacy Policy
Terms of Use
Contact Us

7ads6x98y